Testing for HSV-2 follows two fundamentally different paths depending on whether you have visible sores or not. If you have an active outbreak, a swab test taken directly from a lesion is fast and highly accurate. If you have no symptoms, a type-specific blood test can detect antibodies your immune system builds against the virus. Both approaches have trade-offs, and understanding those trade-offs matters because a surprising number of HSV-2 carriers never realize they are infected, and some test results can be misleading if you do not know how to interpret them.
Swab Testing During an Active Outbreak
When blisters, sores, or ulcers are present, the most reliable approach is a polymerase chain reaction (PCR) swab. A clinician rubs the base of an open lesion with a swab, and the sample is tested for viral DNA. PCR is sensitive enough to pick up the virus even when a sore is starting to heal and viral load is dropping. In head-to-head comparisons, PCR caught the virus in cases that traditional viral culture missed: one study found culture’s sensitivity was only about 81% compared with PCR, while both methods had perfect specificity, meaning neither produced false positives.1PubMed. A comparison of PCR with virus isolation and direct antigen detection for diagnosis and typing of genital herpes A separate study in neonatal swab specimens confirmed the same pattern, with PCR achieving 100% sensitivity versus 50% for culture.2PubMed Central. Comparison of Herpes Simplex Virus PCR with Culture for Virus Detection in Multisource Surface Swab Specimens from Neonates
Viral culture, once the standard, is now mostly a backup. It requires a fresh, unroofed lesion and takes days to return results, and its accuracy drops sharply once a sore begins crusting over. PCR also automatically tells you whether the virus is type 1 or type 2, which matters for prognosis and counseling since HSV-2 recurs genitally far more often than HSV-1. If your provider offers a culture rather than PCR, it is worth asking whether PCR is available, particularly if the lesion is not brand new.
Blood Tests When No Lesion Is Present
If you have no active sore, there is nothing to swab, and that is where blood-based antibody testing comes in. Type-specific IgG blood tests work by detecting antibodies your body produces against a protein called glycoprotein G, which differs between HSV-1 and HSV-2. Because the glycoprotein G on HSV-2 has a unique region not shared with HSV-1, a well-designed assay can distinguish the two types.3PubMed. Localization of type-specific epitopes of herpes simplex virus type 2 glycoprotein G recognized by human and mouse antibodies Several commercial assays use this approach.4PubMed Central. Evaluation of three glycoprotein G2-based enzyme immunoassays for detection of antibodies to herpes simplex virus type 2 in human sera
These tests are useful in several situations: confirming whether a recurrent genital symptom is actually herpes, testing a sexual partner of someone with known HSV-2, screening people living with HIV, and evaluating risk in certain prenatal scenarios.5Clinical Infectious Diseases. Serological Testing for Herpes Simplex Virus (HSV)–1 and HSV-2 Infection They are not, however, as straightforward as a standard STI panel, and anyone getting one should understand the limitations before looking at their results.
The Window Period Problem
After a new HSV-2 infection, your body needs time to build detectable antibodies. If you get tested too soon, you can receive a negative result even though you are infected. One study tracking seroconversion found that the median time to detectable HSV-2 antibodies was about 13 days, but the range was enormous, stretching from as few as 2 to 3 days out to more than 3 months in some individuals.6PubMed Central. Ability of a rapid serology test to detect seroconversion to herpes simplex virus type 2 glycoprotein G soon after infection Most guidelines recommend waiting at least 12 weeks after a possible exposure before relying on a blood test result. Testing earlier can be done, but a negative result at that point does not rule anything out and may need to be repeated.
Why Low-Positive Results Need a Second Look
The biggest practical issue with HSV-2 blood testing is false positives, and they cluster in a predictable zone. IgG assays report an index value: below 0.9 is negative, above 1.1 is positive, and the range between is equivocal. But not all positives are created equal. A 2024 study evaluating three widely used automated platforms found that at low-positive index values (below 3.0), one assay produced false positives roughly 21% of the time for HSV-2. When the researchers calculated what this means at the population level, given an estimated HSV-2 prevalence of about 12% in the United States, the positive predictive value for that assay was just 69%, meaning nearly one in three positive results was wrong.7PubMed Central. Performance characteristics of highly automated HSV-1 and HSV-2 IgG testing Two other platforms performed considerably better, with positive predictive values above 87% and 96% respectively.
A separate analysis using an inhibition-based confirmatory method reinforced this pattern. Among samples with low-positive screen values, 56% failed to confirm as true positives.8PubMed Central. Relationship Between HSV-1 Serostatus and HSV-2 IgG Confirmation Results Using an Inhibition Assay High-positive samples were far more reliable, with only about 14% failing confirmation. The practical takeaway is simple: if your IgG result comes back positive but the index value is below 3.0, that result needs confirmatory testing before you treat it as a real diagnosis. Many clinicians and patients do not realize this, and a low-positive result delivered without context can cause significant and unnecessary distress.
Confirmatory Options
When a screening IgG comes back in the low-positive zone, there are a few ways to verify the result. The University of Washington Western blot has long been considered the gold standard for HSV type-specific serology and remains an option, though it is only performed at a limited number of reference laboratories. Another widely used approach is the inhibition assay, which checks whether the antibody binding in the original test can be blocked by purified HSV-2 antigen. If blocking reduces the signal substantially, the original positive was likely real; if not, it was probably a false positive.
A commercially available alternative, the Euroline Western blot, is easier for labs to perform. Its sensitivity is consistently high, though its specificity has been shown to vary across different geographic populations.9PubMed Central. Performance of the Euroline Western blot assay in the detection of herpes simplex virus type 2 antibody in Uganda, China and the USA Research comparing results across different screening platforms has also shown that when two different IgG assays disagree on the same sample, the discordant positive is almost always a false positive in the less accurate assay.10Sexually Transmitted Diseases. Characterization of Serum Samples With Discordant Results in 2 Herpes Simplex Virus Type 2 IgG Assays If you receive a positive screening result and want certainty, requesting confirmatory testing is reasonable and worth the extra time and cost.
Avoid IgM Testing
You might encounter clinics or online panels that offer HSV IgM testing, sometimes marketed as a way to detect “new” infection. This is one of the clearest areas of consensus in herpes diagnostics: IgM testing for HSV is unreliable and should not be used. IgM antibodies rise during both initial and recurrent infections, so a positive IgM does not tell you whether the infection is new. Worse, the tests cross-react with other viruses. One study found that 45% of COVID-19 patients tested falsely positive for HSV IgM on one commercial platform, while a different assay run on the same samples came back negative, confirming the results were interference artifacts.11PubMed Central. False positive Herpes Simplex IgM serology in COVID-19 patients correlates with SARS-CoV-2 IgM/IgG seropositivity If a provider orders HSV IgM, push back and ask for type-specific IgG instead.
Why Routine Screening Is Not Recommended
Given that a blood test exists, you might wonder why HSV-2 is not part of standard STI panels. The US Preventive Services Task Force has twice reviewed the evidence and recommended against serologic screening for genital herpes in asymptomatic adults without known exposures. The reasoning centers on the false-positive problem described above, combined with a lack of proven benefit from treating asymptomatic carriers at the population level.12JAMA. Serologic Screening for Genital Herpes: An Updated Evidence Report and Systematic Review for the US Preventive Services Task Force Their updated review reiterated that the foundational concern remains poor screening test accuracy, especially in populations with low HSV-2 prevalence, and uncertain benefit from preventive antiviral medication.13JAMA. Serologic Screening for Genital Herpes: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force
International guidelines align with this position. A review of global screening policies noted that the key limitations driving recommendations against universal screening include poor test specificity, no curative therapy, no demonstrated benefit at a population level, and concern about psychosocial harm from diagnosis.14PubMed Central. Herpes Simplex Virus Type 2 Screening in Persons with and Without HIV: Evidence, Challenges, and Future Directions None of this means testing is never appropriate. It means the blanket “test everyone” approach does more harm than good, and testing should be guided by clinical context.
When Testing Without Symptoms Does Make Sense
Even though universal screening is discouraged, several specific scenarios justify testing in the absence of active lesions. Expert recommendations have identified the following groups as most likely to benefit from type-specific serologic testing:15Clinical Infectious Diseases. Recommendations for the Selective Use of Herpes Simplex Virus Type 2 Serological Tests
- Partners of known carriers: If your sexual partner has HSV-2, knowing your own status helps you make informed decisions about suppressive therapy, condom use, and risk during pregnancy.
- People with HIV: HSV-2 co-infection can increase HIV viral shedding and may affect disease management, making awareness of HSV-2 status clinically relevant.
- People at higher STI risk: Those with multiple partners or other STI diagnoses who are motivated to reduce their sexual risk may benefit from knowing their HSV-2 status.
- Recurrent symptoms of uncertain cause: If you repeatedly experience genital irritation, fissures, or atypical symptoms that have never been definitively diagnosed, serology can reveal whether HSV-2 is the underlying cause.
The Reality of Asymptomatic Infection
A major reason testing matters even without symptoms is that HSV-2 sheds from genital skin even when no sore is visible. A study that collected daily genital swabs from hundreds of participants found that people with known symptomatic HSV-2 shed virus on about 20% of days, while people with asymptomatic HSV-2 infection shed on about 10% of days. Even subclinical shedding, meaning viral detection on days with no symptoms at all, occurred at a rate of roughly 9% among asymptomatic individuals.16PubMed Central. Genital Shedding of Herpes Simplex Virus Among Symptomatic and Asymptomatic Persons with HSV-2 Infection The amount of virus shed during those subclinical episodes was similar regardless of whether the person had ever had a recognized outbreak.
A separate study enrolled people who tested positive for HSV-2 antibodies but reported no history of genital herpes and monitored them prospectively. About 62% of those individuals eventually recognized typical herpes lesions once they knew what to look for, though their outbreaks were milder and less frequent than in people with previously diagnosed infection.17PubMed. Reactivation of genital herpes simplex virus type 2 infection in asymptomatic seropositive persons The implication is that many people labeled “asymptomatic” are not truly without symptoms. They simply never connected mild or atypical symptoms to herpes. Testing, in this context, can reframe what someone thought was razor burn, a yeast infection, or a minor skin irritation.
HSV-2 and HIV Risk
One of the strongest clinical arguments for targeted HSV-2 testing relates to its interaction with HIV. HSV-2 creates microscopic breaks in genital mucosa and recruits the very immune cells that HIV targets, substantially increasing vulnerability to HIV acquisition. A large meta-analysis found that pre-existing HSV-2 infection roughly tripled the risk of acquiring HIV in general populations and roughly doubled the risk among higher-risk groups. New HSV-2 infection carried an even higher risk, with an almost five-fold increase in HIV acquisition among general populations during the period shortly after initial HSV-2 infection.18The Lancet Infectious Diseases. Effect of HSV-2 infection on subsequent HIV acquisition: an updated systematic review and meta-analysis
Data from multiple African cohorts have reinforced this relationship. In a study of women in Uganda and Zimbabwe, HSV-2 seropositivity was associated with a roughly three- to nine-fold increase in HIV acquisition risk depending on the population and whether the HSV-2 infection was long-standing or recent.19AIDS. Incident and prevalent herpes simplex virus type 2 infection increases risk of HIV acquisition among women in Uganda and Zimbabwe A vaccine trial analysis found a similar pattern: HSV-2-positive participants who received a placebo had about a three-fold higher risk of acquiring HIV compared with HSV-2-negative participants.20PubMed Central. Impact of Herpes Simplex Virus Type 2 on HIV-1 acquisition and progression in an HIV vaccine trial (the Step Study) In regions with high HIV prevalence, knowing your HSV-2 status can be a meaningful part of HIV prevention planning.
Testing in Pregnancy
Neonatal herpes is rare but devastating, and the highest-risk scenario is when a mother acquires HSV-2 for the first time near delivery, because she has no antibodies to pass to the baby and may be shedding large amounts of virus. Testing in pregnancy is not universally recommended, but targeted serologic testing of couples can be valuable. A study of neonatal herpes cases found that maternal age under 25 and unknown or very young paternal age were significant risk factors. Testing couples with at least one of those risk factors would require screening about 36% of pregnancies but could potentially prevent up to 60% of neonatal herpes cases.21PubMed. Targeted prenatal herpes simplex virus testing: can we identify women at risk of transmission to the neonate? Where both partners are tested, a common use case is identifying a seronegative pregnant woman whose partner is HSV-2 positive, so that precautions such as abstinence or antiviral suppression can be taken in the third trimester.
Psychosocial Effects of a Positive Result
Concern about emotional harm from an HSV-2 diagnosis is one of the reasons cited against broad screening. But the research on this topic paints a more nuanced picture than you might expect. A systematic review of nine studies found that in seven of them, an HSV-2 diagnosis through serologic testing did not produce lasting negative effects on mental health, sexual satisfaction, or quality of life. Two studies did find some negative impact: one noted increased distress in a small group of college students at three months, and the other found self-reports of feeling sexually undesirable lasting up to a year. Interestingly, participants who anticipated a herpes diagnosis before testing rated it as moderately severe, while those who actually tested positive reported the perceived severity as lower than they had expected.22Sexually Transmitted Infections. Herpes simplex virus type 2 serological testing and psychosocial harm: a systematic review The review’s conclusion was that concerns about sustained emotional impact should not deter clinicians from offering testing to appropriate patients.
That said, context matters. Receiving a positive result without counseling, without understanding that the index value may need confirmation, and without knowing that many people with HSV-2 live entirely normal sexual and reproductive lives can amplify distress unnecessarily. The emotional challenge is less about the diagnosis itself and more about the quality of information that accompanies it.
Cross-Reactivity Between HSV-1 and HSV-2
Because HSV-1 (which causes most oral cold sores) and HSV-2 are closely related, some antibody tests can confuse the two. Glycoprotein G-based IgG assays were specifically designed to minimize this problem, but cross-reactivity is not zero. One evaluation of a point-of-care device found that about 2.6% of samples that were positive only for HSV-1 IgG triggered a false positive on the HSV-2 test. Small amounts of cross-reactivity were also seen with antibodies to other herpesviruses.23PubMed Central. Rapid, sensitive, and specific lateral-flow immunochromatographic point-of-care device for detection of herpes simplex virus type 2-specific immunoglobulin G antibodies in serum and whole blood This is another reason low-positive results deserve extra scrutiny: if you have known HSV-1 and your HSV-2 IgG comes back with a borderline-positive index value, the odds of a false positive are meaningfully higher.
Emerging Diagnostic Technologies
The current testing landscape may not remain static. Researchers are developing rapid isothermal amplification tests that combine enzymes with CRISPR-based detection systems. One such assay, built on a platform called SHERLOCK, was able to detect and type HSV from genital swabs with about 95% sensitivity and 100% specificity for HSV-2, using a simple fluorescence readout that could eventually be adapted for point-of-care use.24iScience. A rapid isothermal CRISPR-Cas13a diagnostic test for genital herpes simplex virus infection The appeal of this kind of technology is speed and portability: unlike PCR, which requires expensive lab equipment, isothermal amplification can run at a single temperature, potentially making accurate genital herpes testing feasible in clinics without specialized laboratories. These tools remain in the research phase, but they represent a direction that could eventually address some of the accuracy and access problems that plague current serologic options.